A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

被引：0

作者：

Fowler, Nathan ^{[1
]}

McLaughlin, Peter ^{[1
]}

Hagemeister, Fredrick B. ^{[1
]}

Kwak, Larry ^{[1
]}

Fanale, Michelle ^{[1
]}

Neelapu, Sattva ^{[1
]}

Fayad, Luis ^{[1
]}

Pro, Barbara ^{[1
]}

Sergent, Crystal ^{[1
]}

White, Shana R. S. ^{[1
]}

Samaniego, Felipe ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：683 / 683

页数：1

共 50 条

[41] Rituximab for the therapy of non-Hodgkin's lymphoma [J].

Rummel, M. J. .

ONKOLOGE, 2007, 13 (03) :227-+

[42] Hepatitis C virus infection in patients with B-cell non-Hodgkin's lymphoma. [J].

Zuckerman, T ;

Zuckerman, E ;

Douer, D ;

Fong, TL ;

Nathwani, BN ;

Velankar, M ;

Gutekunst, K ;

Qian, GD ;

Levine, AM .

BLOOD, 1996, 88 (10) :877-877

[43] Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma [J].

Martinelli, G ;

Laszlo, D ;

Bertolini, F ;

Pastano, R ;

Mancuso, P ;

Calleri, A ;

Vanazzi, A ;

Santoro, P ;

Cavalli, F ;

Zucca, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (02) :271-277

[44] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma [J].

van der Jagt, Richard H. ;

Cohen, Philip ;

Cheson, Bruce D. ;

Tulpule, Anil ;

Herst, Jordan A. ;

Lemieux, Bernard ;

Schwartzberg, Lee S. ;

Robinson, K. Sue ;

Oliver, Jennifer W. ;

Williams, Michael E. .

ANNALS OF ONCOLOGY, 2006, 17 :200-200

[45] PHARMACOKINETICS AND TOLERABILITY OF OFATUMUMAB AND BENDAMUSTINE IN PATIENTS WITH INDOLENT B-CELL NON-HODGKIN'S LYMPHOMA [J].

Forero-Torres, A. ;

Chandler, J. C. ;

Iyer, S. P. ;

Kanate, A. S. ;

Quinlan, M. ;

Hoever, P. ;

Izquierdo, M. ;

Duval, V. ;

Madan, S. .

HAEMATOLOGICA, 2017, 102 :469-469

[46] Combination chemotherapy of rituximab, fludarabine, mitoxantrone and dexamethasone for refractory or bulky indolent B-cell lymphoma. [J].

Tsukada, J ;

Machida, S ;

Ogawa, R ;

Morimoto, H ;

Higashi, T ;

Mizobe, T ;

Ota, T ;

Kubota, A ;

Iwashige, A ;

Kawano, I ;

Toda, Y ;

Tanaka, Y .

BLOOD, 2003, 102 (11) :304B-304B

[47] Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity [J].

Dean, Robert ;

Pohlman, Brad ;

Rybicki, Lisa ;

Maggiotto, Amanda L. ;

Bates, Jennifer ;

Smith, Stephen D. ;

Bolwell, Brian J. ;

Sweetenham, John .

BLOOD, 2011, 118 (21) :705-705

[48] Rituximab, ifosfamide, mesna, and etoposide (RIME) with or without mitoxantrone (RIME-N) as therapy for refractory B-cell non-Hodgkin's lymphoma. [J].

Somer, BG ;

McDaid, K ;

Tsai, D ;

Green, R ;

Mick, R ;

Retter, A ;

Porter, DL ;

Laport, GG ;

Luger, SM ;

Downs, L ;

Stadtmauer, EA ;

Schuster, SJ .

BLOOD, 2000, 96 (11) :248B-248B

[49] Bendamustine for indolent non-Hodgkin lymphoma in the front-line or relapsed setting: a review of pharmacokinetics and clinical trial outcomes [J].

van der Jagt, Richard .

EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (05) :525-537

[50] Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study [J].

Kahl, Brad S. ;

Bartlett, Nancy L. ;

Leonard, John P. ;

Chen, Ling ;

Ganjoo, Kristen ;

Williams, Michael E. ;

Czuczman, Myron S. ;

Robinson, K. Sue ;

Joyce, Robin ;

van der Jagt, Richard H. ;

Cheson, Bruce D. .

CANCER, 2010, 116 (01) :106-114

← 1 2 3 4 5 →